Showing results (1-10 of 934) with videos related to
Sort By:
Pageof 94
Plos One|September 11, 2014
Activation of Cre recombinase alone can induce complete tumor regressionYulin Li, Peter S Choi, Stephanie C Casey, et al.Molecular & Cellular Oncology|June 17, 2016
miR-17-92 explains MYC oncogene addictionYulin Li, Stephanie C Casey, Peter S Choi, et al.Cancer Cell|August 14, 2014
MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic stateYulin Li, Peter S Choi, Stephanie C Casey, et al.Immunologic Research|May 6, 2014
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivationStephanie C Casey, Yulin Li, Dean W FelsherProceedings of the National Academy of Sciences of the United States of America|July 30, 2014
Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistancePeter S Choi, Yulin Li, Dean W FelsherJournal for Immunotherapy of Cancer|August 5, 2014
Oncogene withdrawal engages the immune system to induce sustained cancer regressionStephanie C Casey, Yulin Li, Alice C Fan, et al.Oncotarget|April 21, 2016
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemiaYulin Li, Anja Deutzmann, Peter S Choi, et al.Trends in Immunology|February 25, 2017
MYC: Master Regulator of Immune PrivilegeStephanie C Casey, Virginie Baylot, Dean W FelsherBlood|March 9, 2018
The MYC oncogene is a global regulator of the immune responseStephanie C Casey, Virginie Baylot, Dean W FelsherCurrent Opinion in Immunology|April 11, 2013
Noncanonical roles of the immune system in eliciting oncogene addictionStephanie C Casey, David I Bellovin, Dean W FelsherPageof 94